Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours

PHASE3CompletedINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

August 31, 2016

Study Completion Date

September 30, 2024

Conditions
Stage I Testicular Non-Seminomatous Germ Cell Tumor
Interventions
DRUG

BEP(500)

"One cycle of BEP(500):~Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15"

Trial Locations (35)

SE1 9RT

Guy's Hospital, London

NN6 8BJ

Northampton General Hospital NHS Trust, Northampton

CF14 2TL

Velindre Cancer Center at Velindre Hospital, Cardiff

Unknown

Aberdeen Royal Infirmary, Aberdeen

Ysbyty Gwynedd, Bangor

Queen Elizabeth Hospital, Birmingham

Royal Sussex County Hospital, Brighton

Bristol Haematology and Oncology Centre, Bristol

Queen's Hospital, Burton-on-Trent

Addenbrooke's Hospital, Cambridge

Cheltenham General Hospital, Cheltenham

Gloucestershire Royal Hospital, Cheltenham

University Hospitals Coventry and Warwickshire NHS Trust, Coventry

Royal Derby Hospital, Derby

Western General Hospital, Edinburgh

Royal Devon and Exeter Hospital, Exeter

Beatson West of Scotland Cancer Centre, Glasgow

Royal Surrey County Hospital, Guildford

Castle Hill Hospital, Hull

Ipswich Hospital, Ipswich

St James's University Hospital, Leeds

Leicester Royal Infirmary, Leicester

Lincoln County Hospital, Lincoln

Clatterbridge Centre for Oncology, Liverpool

Royal Liverpool University Hospital, Liverpool

St Bartholomew's Hospital, London

University College Hospital, London

Maidstone Hospital, Maidstone

James Cook University Hospital, Middlesbrough

Norfolk and Norwich University Hospital, Norwich

Nottingham City Hospital, Nottingham

Churchill Hospital, Oxford

Weston Park Hospital, Sheffield

Southampton General Hospital, Southampton

Royal Marsden Hospital, Sutton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University Hospital Birmingham NHS Foundation Trust

OTHER

collaborator

Cancer Research UK

OTHER

lead

Institute of Cancer Research, United Kingdom

OTHER